Microba Life Sciences Limited
AASX:MAP0.04
AUD
+0.00
(-2.50%)
ISIN
AU0000209868
Return %
Stock
S&P 500
1Y
-50.00
14.20
3Y
-87.09
81.12
5Y
- -
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Geoffrey Cockerill
- Full Time Employees
- 80
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- 324 Queen Street Brisbane QLD Australia 4000
- IPO Date
- Apr 1, 2022
- Website
- microba.com
- Similar Companies
- Business
- Microba Life Sciences Limited is an Australia-based precision microbiome company specializing in microbiome testing and analysis, therapeutic discovery, and diagnostic services focused on the human gut microbiome. The company’s core offerings include advanced metagenomic testing under brands such as MetaPanel for pathogen detection and microbiome profiling, personal and research microbiome testing services, dietary supplements marketed primarily in the UK under the Invivo brand, and a data-driven therapeutics platform targeting treatments for diseases including ulcerative colitis, inflammatory bowel disease, and autoimmune conditions. Microba operates through two primary segments: Testing Services and Supplements, and Research and Development, serving customers across Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. Founded in 2017 and headquartered in Brisbane, Australia, Microba has expanded its global footprint through key strategic moves. Recent major changes include the December 2023 acquisition of UK-based Invivo Clinical Limited for approximately £11 million, enhancing its clinical testing and supplement capabilities. The company retired older brands such as Co-Biome and Metaxplore in Australia while continuing Invivo supplements in the UK. In 2024, Microba transferred its Research Services business unit to Clinical Microbiomics A/S, focusing its efforts on diagnostics and therapeutics development. Additionally, Microba strengthened its governance with a new board appointment in November 2025 to support its global commercial expansion and microbiome innovation strategy. Its major strategic partnership includes a significant equity investment by Sonic Healthcare, which holds a substantial stake and supports commercial growth. Microba Life Sciences continues to lead in microbiome science with high-throughput, quality-assured testing and development of therapeutics and diagnostics aimed at improving human health worldwide.